|Articles|April 1, 2017

BioPharm International

  • BioPharm International-04-01-2017
  • Volume 30
  • Issue 4

Peristaltic Pump with Single-Use Cartridge Technology

The Quantum Pump from Watson Marlow Fluid Technology Group is a peristaltic pump with patented ReNu single-use (SU) cartridge technology.

The Quantum Pump from Watson Marlow Fluid Technology Group is a peristaltic pump with patented ReNu single-use (SU) cartridge technology. Quantum enables higher downstream process yields throughout the pressure range, delivering virtually pulse-free linear flow and low shear. Flow linearity is achieved across the 43.5 psi (3 bar) single-use processing pressure range up to 5.3 gallons per minute with trace pulsation of only ± 1.74 psi (±0.12 bar). An integrated 4000:1 speed control ratio allows users to sustain constant transmembrane pressure in micro and ultrafiltration. The user interface is located at the front of the pump, enabling visual confirmation of operating state and easy access to pump controls even when skid mounted.

The ReNu SU cartridge technology enables the pump’s aseptic fluid paths to be positioned accurately. The cartridge slides into position, allowing for a change of fluid path. Quantum’s ReNu SU cartridge offers validation and extractable data in line with BioPhorum Operations Group (BPOG), Bio-Process Systems Alliance, United States Pharmacopoeia, and International Organization for Standardization guidelines. Suitable for gamma irradiation up to 50 kilogray, ReNu SU is manufactured in an ISO Class 7 cleanroom, with all contact material tested for biocompatibility and BPOG-derived extractable studies. 

Watson Marlow Fluid Technology Group


Related to this article

The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
FDA grants accelerated approval to Johnson & Johnson’s subcutaneous EGFR/MET bispecific Rybrevant Faspro for previously treated head and neck squamous cell carcinoma, T-Therapeutics raises a $133 million Series B to take TCR-CD3 bispecifics into clinical trials, and Alethio Therapeutics raises a $90 million Series A to advance its first-in-class G6B antibody for essential thrombocythemia.
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
China’s NMPA grants priority review to Akeso’s PD-1/VEGF bispecific ivonescimab with chemotherapy for first-line biliary tract cancer, VeonGen Therapeutics aligns with FDA on a phase 3 design for its dual-AAV Stargardt gene therapy VG801, and Caldera Therapeutics’ IL-23p19×TL1A bispecific CLD-423 shows a half-life of more than 40 days in a phase 1a trial.